Author

Sang Joon Lee 1

1 Celltrion,Incheon,Korea (Republic of)

A LARGE POOLED SAFETY ANALYSIS OF 3 POST-MARKETING STUDIES CONDUCTED IN INFLAMMATORY BOWEL DISEASE PATIENTS TREATED WITH BIOSIMILAR INFLIXIMAB (CT-P13)

Sang Joon Lee

A Large Pooled Safety Analysis of 3 Post-Marketing Studies Conducted in Inflammatory Bowel Disease Patients Treated with Biosimilar Infliximab (CT-P13)

Sang Joon Lee, KyungMin Baek, Yoon Jee Lee, Sujin Lee, Houng Kim, Seul Gi Lee, Jeong Eun Park

DEVELOPMENT OF A SUBCUTANEOUS FORMULATION OF CT-P13 (INFLIXIMAB): MAINTENANCE SUBCUTANEOUS ADMINISTRATION MAY ELICIT LOWER IMMUNOGENICITY COMPARED TO INTRAVENOUS TREATMENT

Shomron Ben-Horin, Walter Reinisch, Byong Duk Ye, Rene Westhovens, Dae Hyun Yoo, Sang Joon Lee, Sung Young Lee, Mi Rim Kim, Stefan Schreiber

EARLY EFFECTIVENESS IN INFLAMMATORY BOWEL DISEASE PATIENTS WHO WERE TREATED WITH CT-P13

Sang Hyoung Park, Ji Hyun Lee, Suck Ho Lee, Hyeok Jin Kwon, Dong Il Park, Hyung kil Kim, Jae Hee Cheon, Jong Pil Im, You Sun Kim, Sang Joon Lee, Sung Young Lee, Sun Hee Lee, Ti Na Pyo, Young Ho Kim

EVALUATION OF CLINICAL RELATIONSHIP BETWEEN FECAL CALPROTECTIN AND ENDOSCOPIC FINDINGS IN ULCERATIVE COLITIS PATIENTS TREATED WITH INFLIXIMAB (CT-P13) SUBCUTANEOUS AND INTRAVENOUS THERAPY: RESULTS FROM A MULTICENTER, RANDOMIZED, CONTROLLED PIVOTAL TRIAL

Walter Reinisch, Jaroslaw Leszczyszyn, Robert Dudkowiak, Adi Lahat, Beata Gawdis-Wojnarska, Aldis Pukitis, Marek Horynski, Katalin Farkas, Jaroslaw Kierkuś, Maciej Kowalski, Shomron Ben-Horin, Stefan Schreiber, Sang Joon Lee, Sung Hyun Kim, Jee Hye Suh, Yun Ah Kim, Se Ra Kim, Seul Gi Lee, Byong Duk Ye

EXPOSURE-RESPONSE RELATIONSHIP OF SUBCUTANEOUS INFLIXIMAB (CT-P13 SC) IN PATIENTS WITH ACTIVE CROHN'S DISEASE AND ULCERATIVE COLITIS: ANALYSIS FROM A MULTICENTER, RANDOMIZED CONTROLLED PIVOTAL TRIAL

Byong Duk Ye, Jaroslaw Leszczyszyn, Robert Dudkowiak, Adi Lahat, Beata Gawdis-Wojnarska, Aldis Pukitis, Marek Horynski, Katalin Farkas, Jaroslaw Kierkuś, Maciej Kowalski, Stefan Schreiber, Walter Reinisch, Sang Joon Lee, Sung Hyun Kim, Jee Hye Suh, Mi Rim Kim, Han Na Kim, Shomron Ben-Horin

Noninferiority of Novel Subcutaneous Infliximab (CT-P13) to Intravenous Infliximab (CT-P13) in Patients with Active Crohn's Disease and Ulcerative Colitis: Week 30 Results from a Multicentre, Randomised Controlled Pivotal Trial

Stefan Schreiber, Jaroslaw Leszczyszyn, Robert Dudkowiak, Adi Lahat, Beata Gawdis-Wojnarska, Aldis Pukitis, Marek Horynski, Katalin Farkas, Jaroslaw Kierkuś, Maciej Kowalski, Shomron Ben-Horin, Byong Duk Ye, Sang Joon Lee, Sung Hyun Kim, Mi Rim Kim, Han Na Kim, Walter Reinisch

PHASE III RANDOMIZED CONTROLLED TRIAL TO COMPARE BIOSIMILAR INFLIXIMAB (CT-P13) WITH INNOVATOR INFLIXIMAB IN PATIENTS WITH ACTIVE CROHN’S DISEASE: 1-YEAR MAINTENANCE AND SWITCHING RESULTS

Young-Ho Kim, Byong Duk Ye, Marina Pesegova, Olga Alexeeva, Marina Osipenko, Adi Lahat, Andriy Dorofeyev, Ágnes Szabone Salamon, Sigal Fishman, Olena Levchenko, Jae Hee Cheon, Maria Lia Scribano, Radu-Bogdan Mateescu, Kang Moon Lee, Chang Soo Eun, Sang Joon Lee, Sung Young Lee, Alex Kudrin

SUBCUTANEOUS ADMINISTRATION OF A NOVEL FORMULATION OF CT-P13 (INFLIXIMAB BIOSIMILAR) IS SAFE AND ACHIEVES PROJECTED THERAPEUTIC DRUG LEVELS: A PHASE I STUDY IN HEALTHY SUBJECTS

Rene Westhovens, Dae Hyun Yoo, Stefan Schreiber, Walter Reinish, Shomron Ben-Horin, Byong Duk Ye, Jae Woo Kim, Sang Joon Lee, Yeon Ju Jung, Jee Hye Suh, SunJung Kim, Da Hye Kwak

Item 1 - 9 / 10
1